Novartis to buy neuroscience firm Cadent Therapeutics for up to $770m pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.
EML4), producing a unique ALK protein that promotes unchecked, abnormal cell growth. We see it in about 4-5% of our non-small cell lung cancer patients, so it s a small slice of that pie, Shaw told
Medpage Today. But there are so many non-small lung cell cancer patients out there that even 4-5% is still a large absolute number of patients. And that s not just in the U.S., but worldwide.
The development of targeted therapies for
ALK-positive NSCLC over the past dozen years has had a significant impact on the natural history of the disease. According to Shaw, in the absence of the ALK targeted therapies,
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary
by Barry Teater, NCBiotech writer December 16, 2020 .
RESEARCH TRIANGLE PARK – vTv Therapeutics of High Point has out-licensed worldwide development and commercialization rights to its potential kidney disease drug to a California biotech company in a deal that ultimately could be worth more than $150 million.
Under the terms of the agreement, Anteris Bio will pay vTv $2 million up front and up to $151 million for future development, regulatory and commercial sales milestones, as well as royalties on annual net sales. In addition, vTv will receive a minority equity stake in Anteris.
Anteris is a newly formed portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 in Oakland, Calif., by former Novartis CEO Joe Jimenez and Mark Fishman, M.D., former president of the Novartis Institutes for BioMedical Research.
vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio
HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel clinical-stage Nrf2 activator compound, HPP971. Anteris Bio, a newly-formed portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman, will focus on developing HPP971 as a new therapy for the treatment of renal disease.